Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888879 | 0.98 | GAA (0.46) | GAAALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL14487492 | 0.93 | SIGMAR1 (0.44) | GAAALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL20438446 | 0.88 | PIK3CD (0.40) | GAAALDH1A1SMN1; SMN2NPC1CHRM5 | |
| SCHEMBL21454477 | 0.85 | HSD17B10 (0.44) | GAAALDH1A1SMN1; SMN2HTTMEN1 | |
| SCHEMBL21454476 | 0.84 | HSD17B10 (0.42) | GAAALDH1A1SMN1; SMN2NPC1CHRM5 | |
| SCHEMBL18623939 | 0.84 | HSD17B10 (0.42) | GAAALDH1A1SMN1; SMN2NPC1CHRM5 | |
| SCHEMBL24220956 | 0.80 | HSD17B10 (0.47) | ALDH1A1SMN1; SMN2NPC1TDP1CHRM5 | |
| SCHEMBL21764427 | 0.80 | HSD17B10 (0.47) | ALDH1A1SMN1; SMN2NPC1TDP1CHRM5 | |
| SCHEMBL888876 | 0.80 | SIGMAR1 (0.45) | ALDH1A1KMT2ATDP1POLBSIGMAR1 | |
| SCHEMBL10284339 | 0.80 | HSD17B10 (0.47) | ALDH1A1SMN1; SMN2NPC1TDP1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250513-A1 | 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200276211-A1 | COMPOUNDS FOR TREATING NEAR VISION DISORDERS | VIEWPOINT THERAPEUTICS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-12 | — | — | US | disclosed |
| US-8236839-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120165288-A1 | AZAPEPTIDE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2012-06-28 | — | — | US | disclosed |
| US-8158805-B2 | Azapeptide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-7887835-B2 | for vascular lesion imaging and for diagnosing arteriosclerosis, ischemia with X-ray angiography and positron emission tomography; fluorinated steroid ester, glyceride compounds, phosphatidylcholine, and phosphatidylserine as membrane components of liposome | FUJIFILM CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20110009355-A1 | Azapeptide Derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20090036357-A1 | Azapeptide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-7235580-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276211-A1 | COMPOUNDS FOR TREATING NEAR VISION DISORDERS | CRYAB, PDE6C, CRYAA | GAA 875/4885ALDH1A1 1412/4885SMN1; SMN2 3368/4885 |
| US-20120165288-A1 | AZAPEPTIDE DERIVATIVES | SAMHD1, ENTPD5, DNPEP | GAA 37/4885ALDH1A1 3218/4885SMN1; SMN2 3772/4885 |
| US-20120088919-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | GAA 2216/4885ALDH1A1 2963/4885SMN1; SMN2 4218/4885 |
| US-20180194768-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | GAA 17/4885ALDH1A1 1439/4885SMN1; SMN2 3460/4885 |
| US-20090036357-A1 | Azapeptide derivatives | SAMHD1, ENTPD5, DNPEP | GAA 37/4885ALDH1A1 3218/4885SMN1; SMN2 3772/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | GAA 16/4885ALDH1A1 1111/4885SMN1; SMN2 3296/4885 |
| US-20110009355-A1 | Azapeptide Derivatives | SAMHD1, ENTPD5, DNPEP | GAA 37/4885ALDH1A1 3218/4885SMN1; SMN2 3772/4885 |
| US-20190016723-A9 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | GAA 17/4885ALDH1A1 1194/4885SMN1; SMN2 3454/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | GAA 2692/4885ALDH1A1 1037/4885SMN1; SMN2 4884/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | GAA 17/4885ALDH1A1 1194/4885SMN1; SMN2 3454/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | GAA 354/4885ALDH1A1 1273/4885SMN1; SMN2 985/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | GAA 1125/4885ALDH1A1 2295/4885SMN1; SMN2 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.